AtriCure, Inc. (ATRC) News

AtriCure, Inc. (ATRC): $75.92

0.62 (+0.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ATRC News Items

ATRC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ATRC News From Around the Web

Below are the latest news stories about AtriCure Inc that investors may wish to consider to help them evaluate ATRC as an investment opportunity.

AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?

AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | April 30, 2021

Can You Imagine How Elated AtriCure's (NASDAQ:ATRC) Shareholders Feel About Its 427% Share Price Gain?

For many, the main point of investing in the stock market is to achieve spectacular returns. And we've seen some truly...

Yahoo | April 30, 2021

AtriCure Names B. Kristine Johnson Board Chair

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair. In addition, the Company announced that Scott Drake and Mark Lanning will not stand for re-election at the end of their terms in May 2021.

Yahoo | April 8, 2021

AtriCure to Announce First Quarter 2021 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021.

Yahoo | April 6, 2021

Cardiac Prosthetic Devices Market | Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Boston Scientific Corporation, Edward Lifesciences Corporation BIOTRONIK, Braile Biomedica, CryoLife, Inc., Labcor Laboratrios

Cardiac Prosthetic Devices Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players

OpenPR | March 23, 2021

Radiofrequency Ablation Devices Market Overview, Top Players Analysis, Business Development Strategies and Sales Revenue 2027 | AngioDynamics, Inc., Hologic, Inc., AtriCure, Inc., and Johnson & Johnson

A new report published by Allied Market Research titled, "Radiofrequency Ablation Devices Market was valued at $1,729 million in 2015, and is expected to reach $3,785 million by 2022, supported by a CAGR of 11.8% during the forecast period 2016-2027" Download

OpenPR | March 17, 2021

Atrial Fibrillation Market to reach US$ 18,085.96 million by 2027 and to grow at a CAGR of 14.0% - AtriCure, Biosense Webster, CardioFocus, Biotronik

Atrial fibrillation also referred to as AFib or AF is a medical condition that causes irregular heartbeat (arrhythmia) and which can further lead to blood clots, stroke, heart failure and other heart-related complications. The global atrial fibrillation market is driven

OpenPR | March 8, 2021

AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.

Yahoo | March 2, 2021

AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript

ATRC earnings call for the period ending December 31, 2020.

Yahoo | February 24, 2021

AtriCure: Q4 Earnings Insights

Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 51.35% year over year to ($0.18), which beat the estimate of ($0.28). Revenue of $57,725,000 declined by 5.86% from the same period last year, which missed the estimate of $58,100,000. Guidance Atricure Sees FY21 Adj. EBITDA Loss $10M, Adj. EPS $(1.15), Sales ~$250M Atricure Sees Q1 Sales $55M-$57M vs $59.3M Estimate, Adj. EPS $(0.39)-$(0.36) Conference Call Details Date: Feb 23, 2021 Time: 04:30 PM View more earnings on ATRC ET Webcast URL: https://edge.media-server.com/mmc/p/7888agea Technicals 52-week high: $67.01 52-week low: $23.16 Price action over last quarter: Up 69.55% Company Overview AtriCure Inc an atrial fibrillation solutions com...

Yahoo | February 23, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5725 seconds.